7 results
Primary Objectives • To demonstrate if the impairment of cognitive function caused by mecamylamine administration can be diminished by an nAChR agonist or CEI.• To evaluate to what extent a single dose of 30 mg mecamylamine may cause a more…
Primary ObjectiveTo evaluate the efficacy of lumacaftor in combination with ivacaftor throughat Week 24 in subjects with cystic fibrosis (CF) who are homozygous for the F508del CFTR mutation on the CF transmembrane conductance regulator (CFTR)…
The goal of the current investigation is to test a new model that accounts better for results of pharmacological research. This model states that the cholinergic system underlies disengagement, and that the noradrenergic system underlies bias. Two…
The specific goals of the study are:- To identify which dose(s) of mecamylamine cause cognitive and memory impairment as demonstrated using the NeuroCart CNS test battery- To investigate the safety and tolerability of mecamylamine by comparison with…
To evaluate the efficacy and pharmacodynamics (PD) of ELX/TEZ/IVA
Primary Objective:To evaluate the efficacy of ELX/TEZ/IVA in subjects 6 through 11 years of age with CF, heterozygous for F508del and a MF mutation (F/MF)Secondary Objectives:• To evaluate the PD of ELX/TEZ/IVA• To evaluate the safety of ELX/TEZ/IVA
To evaluate the efficacy of VX-121/TEZ/D-IVA in CF subjects who are homozygous forF508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, orhave at least 1 other TCR CFTR mutation and no F508del mutation